Abstract: A high internal phase emulsion composition comprising: a) at least three components; b) component A is a polymer, monomer or mixture thereof; c) component B is a polymer; d) component C is a compatiblizer; e) substantially no voids; and wherein the volume fraction of component A represents at least about 80% by volume of the total volume of components A, B and C; and wherein the volume fraction of component B represents less than about 20% by volume of the total volume of components A, B and C; and wherein at least two phases are formed, a phase containing a majority of component A is discrete and a phase containing a majority of component B is continuous.

Abstract: A method has been developed to detect the levels of apolipoproteins A-1 and B in saliva, which is correlated with the levels of HDL and LDL in serum, respectively. In unstimulated saliva, the ration of Apo A to Apo B is correlated with the ration of HDL to LDL in serum. Albumin can be used to normalize the sample for dilution. The high degree of correlation in combination with a simple, quick test that can be performed at the site of collection provides a cost effective, patient friendly means to monitor an individual's risk of heart disease. In the preferred embodiment, saliva production is stimulated by means such as breath mint or tart solution (such as lemon) and the effect of dilution controlled by reference to albumin.

Abstract: Microarray technology is a fast-growing field of biomedical research, aiming to investigate changes in molecular features of hundreds of genes. The multiple parallel processing of information generated from matrices of huge numbers of loci on a solid substrate has allowed the gathering of gene signatures defining specific biological states. A new approach has been developed to facilitate this process wherein genes of the same regulatory modality are selected. The transcriptional regulation of these genes is related to the same control element, the E-box, defined by the sequence CACGTG. PCR products of selected regions of all known genes either binding to this sequence or whose expression is dependent on this binding, as well as genes interacting with E-box-binding genes and control genes, are arrayed on a nylon membrane or other appropriate microchip susbstrate, which is then used as an E-box-specific microarray.

Abstract: Proton conducting membranes having improved resistance to methanol crossover are provided, along with methods for their manufacture. In a preferred embodiment, the polymeric membranes are formed by (a) dissolving a polymer, preferably a polyphosphazene, in an organic solvent to form a polymer solution; (b) adding an oxyacid to the polymer solution; (c) optionally, adding water to the polymer solution, preferably in a molar ratio equivalent to the oxyacid; (d) optionally, concentrating the polymer solution; (e) casting the polymer solution on a casting surface, such as one formed of or coated with TEFLON™; and (f) removing the organic solvent, so as to form the polymeric membrane. A particularly useful application for these polymeric membranes is in fuel cells, such as those wherein methanol and oxygen are converted into electrical energy.

Abstract: A radiopaque brachytherapy seed for implantation into a subject includes a biocompatible component, a therapeutically active component including a non-radioactive drug, and a radiopaque marker. The biocompatible component is (a) physically associated with a therapeutically active component and (b) in contact with the radiopaque marker. The brachytherapy seed has a size and shape suitable for passing through the bore of a needle having an interior diameter of less than about 2.7 millimeters (10 gauge).

Abstract: A baby formula is provided having enzymes added to imitate the effect of those present in normal breast milk, aiding digestion of protein, carbohydrate (simple and complex sugars), and lipid. The enzymes are either of procaryotic or eucaryotic origin, isolated from fermentation broth or tissue, or expressed from recombinant gene sequences. The enzymes are provided in a form for addition to the formula prior to feeding the infant or at the time of feeding. In the preferred form, the enzymes are provided in a form that is stable to storage in the formula, but active when the formula reaches the portion of the gastrointestinal tract where the formula would normally be digested. In the most preferred embodiment, the enzymes are provided in a matrix with an enteric coating that releases the enzyme in the upper portion of the intestine. Depending on the formulation, proteases, carbohydrate degrading enzymes such as alpha-amylase, lactase, fructase, and sucrase, or lipases, are added to the formulation.